Decreased expression of haemoglobin beta (HBB) gene in anaplastic thyroid cancer and recovory of its expression inhibits cell growth by Onda, M et al.
Decreased expression of haemoglobin beta (HBB) gene in
anaplastic thyroid cancer and recovory of its expression inhibits
cell growth
M Onda*,1, J Akaishi
1, S Asaka
1, J Okamoto
1, S Miyamoto
1, K Mizutani
1, A Yoshida
2, K Ito
3 and M Emi
1
1Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, Kawasaki, Japan;
2Kanagawa Prefectural Cancer Center,
Department of Surgery, Kanagawa, Japan;
3Ito Hospital, Tokyo, Japan
Anaplastic thyroid cancer (ATC) is one of the most fulminant and foetal diseases in human malignancies. However, the genetic
alterations and carcinogenic mechanisms of ATC are still unclear. Recently, we investigated the gene expression profile of 11
anaplastic thyroid cancer cell lines (ACL) and significant decreased expression of haemoglobin beta (HBB) gene in ACL. Haemoglobin
beta is located at 11p15.5, where loss of heterozygosity (LOH) was reported in various kinds of cancers, including ATC, and it has
been suggested that novel tumour suppressor genes might exist in this region. In order to clarify the meaning of decreased expression
of HBB in ATC, the expression status of HBB was investigated with ACL, ATC, papillary thyroid cancer (PTC) and normal human
tissues. Haemoglobin beta showed significant decreased expression in ACLs and ATCs; however, in PTC, HBB expressed equal to
the normal thyroid gland. In addition, HBB expressed in normal human tissues ubiquitously. To validate the tumour-suppressor
function of HBB, cell growth assay was performed. Forced expression of HBB in KTA2 cell, which is a kind of ACL, significantly
suppressed KTA2 growth. The mechanism of downregulation of HBB in ATC is still unclear; however, our results suggested the
possibility of HBB as a novel tumour-suppressor gene.
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Anaplastic thyroid cancer is one of the most fulminant human
malignancies, with a mean survival time among patients of less
than 1 year after diagnosis, regardless of treatment (Passler et al,
1999; Voutilainen et al, 1999). It is considered that anaplastic
thyroid cancer (ATC) is thought to arise mainly from a
background of differentiated (papillary or follicular) cancer, on
the basis of clinicopathological observations that ATC is often
accompanied by such cells and that anaplastic tumours tend to
arise in patients who had previously been treated for differentiated
cancer of the thyroid (Nakamura et al, 1992; Kitamura et al,
2000a). Little is known about the genetic alterations in anaplastic
thyroid cancer; only TP53 (Kitamura et al, 2000b) and beta-catenin
(Garcia-Rostan et al, 1999) mutations have been discovered in
ATC.
Recently, we investigated the gene expression profile of
anaplastic thyroid cancer cell lines (ACLs) with cDNA microarray
analysis (Onda et al, 2004a) and found the novel gene alterations
that related to ATC/ACL carcinogenesis. The results of microarray
analysis showed that haemoglobin beta (HBB) gene significantly
decreased expression in ACLs, compared to the expression of
normal thyroid gland. (Data will be provided upon request to the
corresponding author.)
Haemoglobin beta locates at 11p15.5 and its main function is
oxygen transporter activity (Thein et al, 1990). The normal adult
haemoglobin (HbA) tetramer consists of two alpha chains and two
beta chains (Yasuda et al, 2002), and it is known that mutant HBB
causes sickle cell anaemia (Persons, 2003). Loss of heterozygosity
(LOH) of this locus has been reported in ovarian cancer (Launonen
et al, 2000), glioma (Schiebe et al, 2001), breast cancer (Xu et al,
2001; Roy et al, 2003), lung cancer (Xu et al, 2001) and paediatric
thyroid carcinoma (Pauws et al, 2001). In addition, our previous
report showed up to 33% of LOH at 11p15 (D11S922) in anaplastic
thyroid cancer (Kitamura et al, 2000a). Considering these facts, it
is fascinating for us to investigate the relation between decreased
expression of HBB and ACL/ATC progression.
In this study, we examined the expression status of HBB in
ACLs, primary ATC and several normal human tissues with the
reverse transcriptase–PCR (RT–PCR) method. In addition,
protein expression was investigated in ATC, papillary thyroid
cancer (PTC), follicular thyroid cancer (FTC), adenoma (FAD) and
chronic thyroiditis (CTH) using the immunohistochemical meth-
od, because, in some cases, it is considered that ATC might derive
from PTC components (Nakamura et al, 1992; Ozaki et al, 1999;
Kitamura et al, 2000a). Next, the efficacy of the overexpression of
HBB to cell growth in KTA2, which is an ACL and where no
expression of HBB was confirmed, was evaluated.
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sMATERIALS AND METHODS
Anaplastic thyroid cancer cell lines
In all, 11 cell lines that were derived from ATC, 8305c, 8505c, ARO,
FRO, TTA1, TTA2, TTA3, KTA1, KTA2, KTA3 and KTA4 were
used for this study. The 8305c and 8505c cell lines were maintained
in Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA,
USA), ARO and FRO cell lines in minimum essential medium, and
the other seven lines in RPMI 1640. All media contained 10% foetal
bovine serum but no antibiotics. The cells were cultured in a 371C
incubator under 5% CO2 atmosphere.
Patients and specimens
Primary ATC, PTC and noncancerous thyroid gland were excised
from 10 patients who underwent surgery at the Ito Hospital,
Tokyo; the samples were frozen immediately and stored at  801C.
All patients had given informed consent according to guidelines
approved by the Institutional Research Board. All tumour speci-
mens that we analysed contained more than 70% tumour cells.
For immunohistochemical analysis, 14 archived paraffin-
embedded samples of ATC and 15 PTC samples were used.
RNA extraction and cDNA synthesis
Extraction of RNA from cell lines and tissues was performed as
described previously (Onda et al, 2004a,b). Using 5mg of RNA as a
template, cDNAs were synthesised in the usual manner. Briefly, the
template was mixed with 1ml of oligo dT12–18 (Invitrogen,
Carlsbad, CA, USA), used for annealing primer and denatured at
701C for 10min. Then, 200U of Reverse Transcriptase II (Wako
Pure Chemical, Tokyo, Japan), reaction buffer, 40U of RNase
inhibitor (Wako Pure Chemical) and 10mmol dNTPs were added.
This mixture was incubated at 421C for 60min, after which the
product was treated with 2U of RNase (Wako pure chemical) at
371C for 20min.
Semiquantitative RT–PCR
In order to evaluate the expression of HBB in ACL, ATC, PTC and
normal human tissues, semiquantitative RT–PCR (SQ–PCR) was
performed. For the comparison, five normal thyroid samples were
served as a control in SQ-PCR. To adjust the amount of transcribed
cDNA, GAPDH was selected as an internal control and SQ-PCR
experiments were carried out as previously described, after
adjustment of the amount of template cDNA (Onda et al, 2004a).
The primer sequences for GAPDH were 50-ggaaggtgaaggtcggagt-30
(forward) and 50-tgggtggaatcatattggaa-30 (reverse). Sequence in-
formation was collected from the NCBI GenBank (http://
www.ncbi.nlm.nih.gov/), and primers for HBB were designed with
Primer 3 software (http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi). The HBB forward primer was 50-ggagatgcctca-
gaaactgc-30 and the reverse primer was 50-aggttggaggtcggaaagtt-30.
SQ-PCR experiments were performed with 1ml of cDNA for
template, 5U of Takara EX Taq (Takara, Otsu, Japan), 1 PCR
buffer (10mM Tris-HCl, 50mM KCl, 1.5mM MgCl2) and reverse
primers in 30ml of total reaction mixture. PCR conditions for each
gene were optimised in their respective linear phases of
amplification.
For the evaluation of differences of HBB expression between
ACL, ATC, PTC and normal thyroid gland, 10ml of each SQ-PCR
product was electrophoresed on a 2.0% agarose gel and stained
with ethidium bromide. After staining, the density of each sample
spot was measured by AlphaImager 3300 (AlphaIonotech, San
Leandro, CA, USA) with background revision. All SQ-PCR
experiments were duplicated.
Quantitative RT–PCR
In order to quantify the expression of HBB in ACL, ATC, PTC
and exogenous expression in cell growth assay, real-time
quantitative RT–PCR (Q-PCR) was performed. Q-PCR was
carried with qPCR Mastermix for Syber Green I (Eurogenetec,
Seraing, Belgium) and ABI 7700 (Applied Biosystems, Foster City,
CA, USA) described previously (Onda et al, 2004b). Primers for
Q-PCR of HBB were the same as those used in the SQ-PCR study.
The template of Q-PCR was the same as that used in SQ-PCR,
where the amount of cDNA monitoring of GAPDH expression
was adjusted.
The expression difference between normal thyroid tissue and
sample X in ACL, ATH and PTC is defined as follows:
DCtX ¼ Ct HBBX   Ct GAPDHX
ðCt HBB; GAPDH arethresholdcyclesfor
amplificationof HBBandGAPDH;respectivelyÞ
DCtN ave ¼ Sumof DCtN1 toDCtN5=5
ðaverageof DCt of fivenormalthyroidtissuesÞ
DDCtX ¼ DCtX   DCtN ave
Expression ratio of HBB to normal thyroid tissue (Sample X/
average of five normal thyroid tissues)¼2
( DDCt X)
Immunohistochemical analysis
To determine protein expression of HBB, we performed
immunohistochemical analyses using 14 paraffin-embedded
samples of primary ATC and 15 PTC samples. ATC and PTC
samples were collected at the Ito Hospital, Tokyo, Japan. In
addition, for the evaluation of HBB expression in FTC, FAD and
CTH, AccuMax thyroid cancer array and thyroid disease array
(ISU ABXIS Co., Ltd, Seoul, South Korea) were applied. Anti-
HBB antibody was used (sc-21757, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) with 1:100 dilutions. Antigens were
microwaved prior to immunostaining with VECTASTAIN Elite
ABC kits (Vector Laboratories Inc., Burlingame, CA, USA) and
Dako ENVISION kits (Dako corporation, Carpinteria, CA, USA)
following the manufacturers’ instructions. The sections were
counterstained with haematoxylin, and then scanned at low
power to identify areas that were evenly stained. Estimates of
the numbers of positive cells were scored as follows: negative,
0%; 1, 1–10%; 2, 11–25%; 3, 26–50%; 4, 450% positive (Saiz
et al, 2002). Two independent investigators performed the
estimation.
Construction of HBB expression vector
The expression vector of HBB was constructed with pcDNA3.1
directional Expression Kit (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instruction with some modifications.
First, to generate a full length of the coding sequence of HBB, PCR
was performed using cDNA that was reverse transcribed from
pooled human placenta RNA. The cloning forward primer was 50-
caccatggtgcatctgactcc-30, and reverse primer was 50-gtga-
tacttgtgggccagggc-30. PCR condition was the same as that used in
SQ-PCR. This reaction generated a 443bp PCR product that
contained CACC sequence in front of the ATG start codon and
deleted TAG stop codon from the original HBB sequence. The PCR
product was electrophoresed with 2.0% NuSieve GTG agarose
(Cambrex Bio Science Rockland Inc., Rockland, ME, USA) and
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sstained with ethidium bromide. The proper size of the PCR
product was excised and nucleic acid extracted with QIAquick Gel
Extraction kit (QIAGEN, Tokyo, Japan). In all, 4ml of gel-extracted
PCR product was ligated into pcDNA3.1 expression vector with
30min incubation at room temperature. The ligated plasmid was
mixed with 100ml of one-shot chemically competent Escherichia
coli (Invitrogen) and incubated on ice for 30min, and then it was
heat shocked at 421C for 30s and placed on ice immediately.
Transformed E. coli was incubated in 300ml of SOC medium
(Invitrogen) at 371C in the orbital shaker, and then 100mlo f
cultured SOC medium was plated on the LB plate containing
100mgml
 1 ampicillin and it was incubated at 371C for overnight.
Several colonies were selected and sequences confirmed in the
usual manner. Proper clone was incubated in LB medium at 371C
overnight and plasmid DNA was extracted using QIAfilter Plasmid
Midi Kit (QIAGEN).
Transfection of HBB to KTA2 cell line and the evaluation
of the exogenous expression of HBB
In order to evaluate the effect of HBB in anaplastic thyroid cancer,
HBB expression vector, pcDNA HBB expression vector was
transfected into KTA2, which did not express HBB originally.
The day before transfection, 1 10
3 of KTA2 cells were plated in a
24-well plate and cultured with the same condition as described
previously. After 24h, the cells reached 60–70% confluence. Prior
to transfection, the medium was changed to fresh RPMI1640. In all,
200ng of pcDNA HBB was mixed up to 50ml of Opti-MEM I
medium (Invitrogen) and siPORT XP-1 (Ambion, Austin, TX,
USA) subsequent to XP-1’s instructions to make pcDNA HBB/XP-1
complex. The complex was transfected into arranged KTA2 and it
was cultured up to 7 days. At the determined time points of days 0,
3, 5 and 7, cells were collected and RNA was extracted with TRIzol
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Figure 1 (A) Expression of HBB in ACLs. Compared to five normal thyroid gland expressions, HBB expression was significantly decreased in ACL
samples. M: size marker, N1–5: normal thyroid, 1: 8305c, 2: 8505c, 3: ARO, 4: FRO, 5: TTA1, 6: TTA2, 7: TTA3, 8: KTA1, 9: KTA2, 10: KTA3, 11: KTA4. (B)
Result of Q-PCR. The average expression of five normal thyroid glands was settled as 1.00, and relative expression ratio compared to normal was calculated.
Average expression of HBB in ACL was below 1% of normal thyroid gland.
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s(Invitrogen, Carlsbad, CA, USA) (Onda et al, 2004b). The
exogenous expression of HBB was confirmed with both SQ-PCR
and Q-PCR in the same manner as described previously.
Cell growth assay
To determine the influence of gene expression of HBB, cell growth
assay (Smith et al, 2003) was carried out. In total, 3000 KTA2 cells
were plated on a 24-well plate and, after 24h, 200ng of pcDNA HBB
plasmid was transfected. Cells were fixed with 10% formalin for
10min at the determined time points, 0, 3, 5 and 7 days after
transfection. After washing two times in water, fixed cells were
stained with 0.1% crystal violet for 10min, and then washed three
times with water to remove the excess crystal violet solution. The
stained crystal violet was eluted with 200ml of 10% acetic acid and the
absorbance of 590nm was measured with a spectrophotometer. The
difference of cell growth was calculated using Student’s t-test. This
statistical procedure was performed by Statview version 5.0 (SAS
Institute Inc., Cary, NC, USA). The experiments were triplicated.
Single-strand conformation polymorphism (SSCP) analysis
of HBB gene
In order to analyse mutation in the HBB gene, PCR-SSCP analysis
was carried out (Onda et al, 1997; Harada et al, 2002). Genomic
DNA was extracted from 11 ACLs in a usual manner. With regard
to the entire coding region of HBB, the first exon to the third exon
were examined. The primers used for SSCP were as follows: (exon
1) 1F: 50-agcaacctcaaacagacacc-30, 1R: 50-gtctccacatgcccagtttc-30,
(exon 2) 2F: 50-ttggtctattttcccaccctta-30, 2R: 50-tcaagcgtcccatagact-
ca-30, (exon 3) 3F: 50-cctcttatcttcctcccacag-30, 3R: 50-gatgct-
caaggcccttcata-30. These primers were designed to cover the
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Figure 2 (A) Expression of HBB in primary thyroid cancer by SQ-PCR. In primary ATC samples, HBB expression was decreased compared to normal
thyroid gland. On the contrary, HBB expression was almost equal to the expression of normal thyroid glands. M: size marker, N1–5: normal thyroid, A1–15,
primary anaplastic thyroid cancer samples (ATC), P1–10, primary PTC samples. (B) Relative expression of HBB to normal thyroid gland is presented.
Haemoglobin beta expression of normal thyroid is the average of five normal thyroid glands. When the expression of normal thyroid was settled as 1.00, the
ratio represented relative expression of HBB in the sample.
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sentire exon of the HBB gene. Heat-denatured PCR product was
electrophoresed on a 6% long ranger gel (Cambrex, East
Rutherford, NJ, USA) with 5% glycerol, 5W for 4h. DNA
fragments were visualised by silver staining using the Plus One
DNA silver-staining kit (Pharmacia Biotech, Tokyo, Japan)
following the manufacturer’s manual.
Methylation-specific PCR in the promoter legion of the
HBB gene
In order to evaluate the methylation status of the promoter region
of the HBB gene, methylation-specific PCR analysis (MSP) was
performed. Genomic DNA from 11 ACLs was bisulphite mod-
ificated using the CpGenome DNA modification kit (CHEMICOM
International, Inc., Temecula, CA, USA) following the manufac-
turer’s instruction. Sequence information of the promoter region of
the HBB gene was downloaded from UCSC genome browser (http://
genome.cse.ucsc.edu/cgi-bin/hgGateway) and primers for MSP were
designed with Methprimer program (http://www.ucsf.edu/urogene/
methprimer/index1.html). Primers used for MSP are as follows: for
methylated DNA (M), forward: 50-ttagaagagttaaggataggtacgg-30;
reverse: 50-taccccacaaaacaataacgac-30; for unmethylated DNA
(UM), forward: 50-ttagaagagttaaggataggtatgg-30; reverse: 50-cttaccc-
cacaaaacaataacaac-30. The size of PCR products was 250 and 252bp.
RESULTS
Expression of HBB in ACLs, primary ATC and PTC
In order to evaluate the expression of HBB in ACLs, SQ-PCR and
Q-PCR were performed. Compared to normal thyroid glands that
were derived from five PTC patients, expression of HBB was
significantly decreased in 11 ACLs (Figure 1A and B). Average
expression of HBB in ACL was below 1% of the average expression
in a normal thyroid gland.
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Figure 4 Upregulated expression of HBB at KTA2 with pcDNA HBB vector. Compared to control (pcDNA empty vector), transfected cells with pcDNA
HBB expression vector showed upregulated expression of HBB at the determined points of days 0, 3, 5 and 7 from the transfection. M, size marker, cont.,
control, pcDNA empty vector, HBB, pcDNA HBB-transfected samples. Ratio, Exogenous expression of HBB against control in each time points, measured
by Q-PCR.
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Figure 5 The results of cell growth assay. (A) Representative image of
KTA2 staining with crystal violet. The cells were stained at 7 days after
transfection. Control, transfected KTA2 with pcDNA empty vector, HBB,
transfected KTA2 with pcDNA HBB expression vector. The experiments
were triplicated. (B) Graphical view of KTA2 cell growth. Compared to
control, pcDNA HBB transfected cell showed growth suppression
(P¼2.4 10
 6, at the point of day 7, t-test).
HBB
GAPDH
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 3 Expression of HBB in 16 normal human tissues. Haemoglobin beta was expressed ubiquitously except in the ovary. M, size marker, 1. Heart, 2.
Whole brain, 3. Placenta, 4. Lung, 5. Liver, 6. Skeletal muscle, 7. Kidney, 8. Pancreas, 9. Spleen, 10. Thymus, 11. Prostate, 12. Testis, 13. Ovary, 14. Small
intestine, 15. Colon, 16. Leukocyte.
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sThen, HBB expression was assessed with ATC and PTC samples.
In ATC, the expression of HBB was significantly decreased as seen
in ACLs, except in one case (A9), with SQ-PCR and Q-PCR assay.
Haemoglobin beta expression in ATC was 0.9–8.6% of normal
thyroid gland expression, besides A8 and A9 cases. On the other
hand, in PTC samples, expression of HBB was 15–98% of normal
thyroid. Even in PTC cases, decreased HBB expression was
observed; however, the expression of HBB in PTC was higher
than that in ATC (Figure 2A and B).
To validate the expression of HBB in other human normal
tissues, SQ-PCR was achieved with 16 human normal tissues. As
shown in Figure 3, HBB was expressed in all tissues, besides the
ovary, with various intensities. These results presented that HBB
was expressed ubiquitously in normal human tissues including the
thyroid gland.
Construction of HBB expression vector and forced
expression in KTA2 cell
Using pcDNA 3.1 plasmid, HBB expression vector, namely pcDNA
HBB, was developed. To confirm forced expression of HBB,
pcDNA HBB was transfected into KTA2 and RNA was collected at
ATC PTC FTC
× 100
× 300
× 100
× 400
× 100
× 300
FAD Chronic thyroiditis
× 100
× 300
× 100
× 300
A
B
Figure 6 Immunohistochemical analysis of HBB expression. (A) Little expression of HBB was confirmed in ATC samples. On the contrary, HBB
expressed in PTC and FTC, mainly stained in cytoplasm. Upper:  100, lower:  300 and  400. (B) Haemoglobin beta expressed in FDA and CTH.
However, less staining was seen in CTH, compared to other histological types.
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sdays 0, 3, 5 and 7. Exogenous expression of HBB within transfected
KTA2 cell line was confirmed with SQ-PCR and Q-PCR analysis
(Figure 4). Compared to the control, HBB expression was
upregulated in transfected KTA2.
Cell growth assays
In order to clarify the effect of HBB in cell growth, cell growth
assay was performed. KTA2 cells that were transfected pcDNA
HBB showed the suppression of cell growth, compared to the
control (Figure 5A). Haemoglobin beta-transfected cells showed a
slow-growing curve (Figure 5B), and, at the point of day 7, the
difference of cell growth between pcDNA HBB-transfected cells
and pcDNA empty vector-transfected cells (control) reached
statistical significance (P¼2.4 10
 6).
Immunohistochemical analysis of HBB expression with
ATC, PTC, FTC, FAD and CTH
To evaluate HBB protein expression, immunohistochemical
analysis was performed with 14 primary ATC and 15 PTC samples.
In addition, using tissue microarray, nine FTC, five FAD and five
CTH samples were assessed. In PTC, HBB expression was
confirmed with strong intensity and the average score was 2.53.
On the contrary, weak expression was seen in ATC samples
(Figure 6A), and the average score was 0.71 (Table 1). In FTC, FAD
and CTH, stronger expression of HBB was seen compared to ATC
samples (Figure 6A and B), and the average staining scores were
3.33, 2.8 and 1.6, respectively.
Mutation analysis of HBB gene
In order to detect the mutation of HBB gene, SSCP analysis was
performed using genomic DNA from 11 ACLs. No mutation from
exon 1 to 3 was seen in 11 ACL samples (Figure 7).
Methylation-specific PCR
To evaluate the methylation status of the HBB promoter region,
MSP assay was carried out with 11 ACL. Within 10 cell lines except
KTA2, PCR product was seen both in M and UM primer sets. Only
KTA2 was not methylated in the promoter region. This result
showed that the promoter region of HBB gene was mainly
hemimethylated and it suggested that methylation was one of the
reasons of downregulation of HBB expression in anaplastic thyroid
cancer (Figure 8).
Table 1 Score of HBB expression with immunostaining method
ATC PTC FTC FAD CTH
Case Score
a Case Score
a Case Score
a Case Score
a Case Score
a
AT-1 1 PT-1 1 D5 3 F4 2 B5 2
AT-2 0 PT-2 3 E1 4 F6 1 C1 1
AT-3 1 PT-3 4 E3 3 G2 4 C3 2
AT-4 0 PT-4 4 F1 4 G4 3 C5 2
AT-5 0 PT-5 2 G1 4 G6 4 D1 1
AT-6 0 PT-6 1 G3 4
AT-7 2 PT-7 4 G5 2
AT-8 0 PT-8 2 F7 4
AT-9 1 PT-9 3 F9 2
AT-10 0 PT-10 1
AT-11 1 PT-11 2
AT-12 2 PT-12 3
AT-13 2 PT-13 4
AT-14 0 PT-14 3
PT-15 1
Ave. 0.71 Ave. 2.53 Ave. 3.33 Ave. 2.8 Ave. 1.6
aEstimates of the numbers of positive cells; negative, 0%, 1, 1–10%; 2, 11–25%; 3,
26–50%; 4, 450% positive.
8305c  KTA2
Exon 1
Exon 2
Exon 3
8505c ARO FRO TTA1 TTA2 TTA3 KTA1 KTA3 KTA4 N1 N2 N3
Figure 7 Results of SSCP analysis of HBB gene with 11 ACLs and three normal thyroid glands. Within coding region from exon 1 to 3, no mutation was
confirmed.
250 bp
252 bp
MM SM M UM M UM UM M UM M UM M UM M UM M UM M UM M UM UM
8305c 8505c ARO FRO TTA1 TTA2 TTA3 KTA1 KTA2 KTA3 KTA4
Figure 8 Results of MSP analysis within the promoter region of HBB gene with 11 ACLs. Generally speaking, all ACL were hemimethylated in the
promoter region except KTA2. Only KTA2 was not methylated in this region.
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sDISCUSSION
Haemoglobin beta is one of the globins chain components of
haemoglobin A, whose basic function is oxygen transport
(Giardina et al, 1995). There are several reasons for the reduction
of HBB expression; for example, partial deletion of the terminal
portion of HBB gene (Orkin et al, 1979), nonsense mutation
(Chang and Kan, 1979) and frameshift deletion (Orkin and Goff,
1981) cause beta-thalassemia.
Genetically, HBB locates at 11p15.5 (Bepler et al, 1999) and this
locus contains embryonic and adult beta-like globin genes that are
ordered as they are expressed during development. High-level
expression of the beta-globin gene cluster is regulated by the locus
control region (LCR) (Sawado et al,2 0 0 3 ) .A l s o ,a tt h i sl o c u s ,l o s so f
imprinting (LOI) had been reported in head and neck squamous cell
cancers (Rainho et al, 2001). Thus, chromosomal location of 11p15.5 is
interesting from the viewpoint of human genetics. In addition, there
were several reports of LOH in various kinds of cancers at this locus. In
this region, there were two distinct tumour-suppressor loci that
implicated breast cancer progression and metastasis (Karnik et al,
1998). It is suggested that an LOH of 11p15.5 might relate to poor
prognosis of nonsmall-cell lung cancer (Bepler et al, 2002). We
previously reported up to 33% LOH at this locus in primary ATC
(Kitamura et al, 2000a). Considering these results, it is highly suggested
that novel tumour suppressor genes might be exist at this locus.
In this report, we showed the significant decreased expression of
HBB in ACL and ATC samples. This is the first report of decreased
expression of HBB in anaplastic thyroid cancer. On the other hand,
HBB expression was seen in normal thyroid gland, PTC, FTC, FAD
and CTH samples. In addition, expression of HBB was observed in
other normal human tissue ubiquitously.
Generally speaking, it is considered that a large part of ATC
arises from differentiated thyroid cancer with anaplastic transfor-
mation (Hunt et al, 2003). Thus, our results suggest the possibility
that loss of expression HBB might relate to anaplastic transforma-
tion of differentiated thyroid cancer.
To clarify the role of HBB in cancer cell growth, cell growth
assay was performed with ACL KTA2, which has no expression of
HBB basically. Interestingly, exogenous expression of HBB
suppressed the cell growth significantly. Our results presented
the possibility of the tumour suppressor activity of HBB. There are
several reasons for gene silencing, including LOH and methylation
of promoter regions. In this study, LOH was not examined because
normal-tumour paired DNA was not available. However, methyla-
tion-specific PCR in ACLs revealed the hemimethylated status of
the promoter region of the HBB gene. With regard to mutation
search, there was no mutation in the coding region of the HBB
gene. Considering these results, it was suggested that methylation
of the promoter region was one of the reasons for the down-
regulation of the HBB gene. However, we could not detect
promoter methylation in KTA2 cell; so it is also suggested that
there might be other mechanisms besides promoter methylation
for the downregulation of HBB expression in anaplastic thyroid
cancer.
Haemoglobin beta is one of the well-investigated genes in the
field of blood diseases. However, nobody paid attention to this
gene in the field of ‘cancer’. Even physiologically, HBB expression
is controlled intricately (Stamatoyannopoulos, 2005). In the
viewpoint of cancer genetics, it strongly required further
examination of the mechanism of the downregulation of HBB in
anaplastic thyroid cancer.
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